People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Graphite Bio, Inc. | — | Biotechnology | Series D+ | $150.7M | $4.9B | 2021 |
| Kamau Therapeutics, Inc. | — | Pharma | Series A | $5.0M | $17.3M | 2025 |
Matthew Porteus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Porteus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Carlo Rizzuto | 1 | 7 |
| Raymond Kelleher | 1 | 4 |
| Abraham Bassan | 1 | 4 |
| Josh Lehrer | 1 | 2 |
| Perry Karsen | 1 | 2 |
| Valentin Barsan | 1 | 2 |
| Katherine Stultz | 1 | 2 |
| Maria Grazia Roncarolo | 1 | 1 |
| Ness Bermingham | 1 | 1 |
| Philip Gutry | 1 | 1 |
| Joe Jimenez | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.